SIETES :: 93167 citas

Resultados de la búsqueda por REGISTROS

1.

Rejón R. El 75% de los ensayos clínicos sobre COVID-19 en España son "no comerciales", pero eso no garantiza un acceso barato . eldiario.es 2020:20 de junio. [Ref.ID 103665]

2.

Moynihan R, Albarqouni L, Nangla C, Dunn AG+, Lexchin J, Bero L. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. BMJ 2020;369:27 de mayo. [Ref.ID 103650]

3.

Luo Q, Qin T. Managing clinical trials for covid-19: the importance of ethics committees. BMJ 2020;369:3 de abril. [Ref.ID 103584]

4.

DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 2020;395:1 de febrero. [Ref.ID 103519]

5.

Wallach JD, Eqilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ 2018;361:24 de mayo. [Ref.ID 102886]

6.

Pacurariu A, Plueschke K, Olmo CA, Kurz X. Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators. Pharmacoepidemiol Drug Saf 2018;27:julio. [Ref.ID 102879]

7.

Jonker CJ, van den Berg HM, Kwa MSG, Hoes AW, Mol PGM. Registries supporting new drug applications. Pharmacoepidemiol Drug Saf 2017;27:1451-7. [Ref.ID 102187]

8.

Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017;26:26 de marzo. [Ref.ID 101903]

9.

Baudard M, Yavchitz A, Ravaud P, Perrodeau E, Boutron I. Impact of searching clinical trial registries in systematic reviews of pharmaceutical treatments: methodological systematic review and reanalysis of meta-analyses. BMJ 2017;356:j448. [Ref.ID 101539]

10.

Jensen AK, Simonsen JE, Ethelberg S. Use of proton pump inhibitors and the risk of listeriosis: a nationwide registry-based case-control study. Clin Infect Dis 2017;64:845-51. [Ref.ID 101519]

11.

Karaca-Mandic P, Meara E, Morden NE. The growing problem of co-treatment with opioids and benzodiazepines. BMJ 2017;356:j1224. [Ref.ID 101495]

12.

Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017;356:j760. [Ref.ID 101494]

13.

Graner S, Svensson T, Beau A-B, Damase-Michel C, Engeland A, Furu K, Hviid A, Haberg SE, Molgaard-Nielsen D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ 2017;356:j629. [Ref.ID 101465]

14.

Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med 2017;376:381-91. [Ref.ID 101395]

15.

Rawshani A, Svensson A-M, Zethelius B, Eliasson B, Rosengren A, Gudbjömsdottir S. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern Med 2016;176:1146-54. [Ref.ID 100702]

16.

Fiore LD. The changing face of clinical trials: integrating randomized comparative effectiveness research with patient care. N Engl J Med 2016;374:2152-8. [Ref.ID 100355]

17.

Dart RC, Green JL. The prescription paradox of acetaminophen safety. Pharmacoepidemiol Drug Saf 2016;25:599-601. [Ref.ID 100266]

18.

Major JM, Zhou EH, Wong H-L, Trinidad JP, Pham TM, Mehta H, Ding Y, Staffa JA, Iyasu S, Wang C, Willy ME. Trends in rates of acetaminophen-related adverse events in the United States. Pharmacoepidemiol Drug Saf 2016;25:590-8. [Ref.ID 100265]